Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230050 | PMC |
| http://dx.doi.org/10.3389/fcimb.2023.1209671 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tertiary Lymphoid Structures as a Biomarker in Immunotherapy and Beyond: Advancing Towards Clinical Application.
Cancer Lett
January 2025
. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Electronic address:
Tertiary lymphoid structures (TLSs) are ectopic immune cell clusters formed in nonlymphoid tissues affected by persistent inflammation, such as in cancer and prolonged infections. They have features of the structure and function of secondary lymphoid organs, featuring central CD20+ B cells, surrounded by CD3+ T cells, CD21+ follicular dendritic cells, and CD68+ macrophages, with a complex vascular system. TLS formation is governed by lymphotoxin-α1β2, TNF, and chemokines like CCL19, CCL21, and CXCL13, differing from secondary lymphoid organ development in developing later in life at sites of chronic inflammation.
View Article and Find Full Text PDFPerspective: Multi-omics and Artificial Intelligence for Personalized Nutritional Management of Diabetes in Patients Undergoing Peritoneal Dialysis.
Adv Nutr
January 2025
Department of Nephrology, The Scarborough Health Network, Toronto, Ontario, Canada; Kidney Life Sciences Institute, Toronto, Ontario, Canada.
Managing diabetes in patients on peritoneal dialysis (PD) is challenging due to the combined effects of dietary glucose, glucose from dialysate, and other medical complications. Advances in technology that enable continuous biological data collection are transforming traditional management approaches. This review explores how multi-omics technologies and artificial intelligence (AI) are enhancing glucose management in this patient population.
View Article and Find Full Text PDFEditorial: Multi-omics approaches in the study of human disease mechanisms.
Front Bioinform
January 2025
Department of Law, Economics and Social Sciences, University Magna Græcia, Catanzaro, Italy.
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma.
Genomics Inform
January 2025
Department of Physiology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer and remains a leading cause of cancer-related deaths worldwide. While traditional approaches like surgical resection and tyrosine kinase inhibitors struggle against the tumor's immune evasion, monoclonal antibody (mAb)-based immunotherapies have emerged as promising alternatives. Several therapeutic antibodies that counter the immunosuppressive tumor microenvironment have demonstrated efficacy in clinical trials, leading to FDA approvals for advanced HCC treatment.
View Article and Find Full Text PDFEditorial: Asbestos and disease genomics: is mesothelioma a genomic paradigm?
Front Toxicol
January 2025
Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!